A benzisothiazole derivative and antipsychotic agent, perospirone, for augmentation of selective serotonin reuptake inhibitors (SSRIs) in refractory obsessive-compulsive disorder (OCD): Two patient case series

International Journal of Psychiatry in Clinical Practice

Volumn 10, Issue 2, 2006, Pages 142-145

  Matsunaga, Hisato ^a   Matsui, Tokuzo ^a   Ohya, Kenzo ^a   Okino, Kenya ^a   Hayashida, Kazuhisa ^a   Maebayashi, Kensei ^a   Kiriike, Nobuo ^c   Stein, Dan ^b  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c NONE

Author keywords

Atypical antipsychotics; Augmentation therapy; Obsessive compulsive disorder; Perospirone; Selective serotonin reuptake inhibitors (SSRIs)

Indexed keywords

DOPAMINE 2 RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PAROXETINE; PEROSPIRONE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CASE REPORT; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HUMAN; JAPAN; MALE; MENTAL PATIENT; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; SCHIZOPHRENIA; SEDATION; SEROTONINERGIC SYSTEM; SIDE EFFECT; SYMPTOM;

EID: 33745058442     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500500487586     Document Type: Article

References (26)

1. Saxena S, Wang D, Bysritsky A, Baxter LR. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996;57:303-6.
2. Stein DJ, Seedat S, Shapira NA, Goodman W. Management of treatment-resistant obsessive-compulsive disorder. In: Pato MT, Zohar J, editors. Current treatment of obsessive-compulsive disorder. 2nd ed. Washington, DC; American Psychiatric Publishing; 2001. p 221.
3. Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder; a single-blind, placebo-controlled study. Int Clin Psychopharmacol 2002;17:115-9.
4. Bogetto F, Bellino S, Vaschetto P, Ziero S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder; A 12-week open trial. Psychiatr Res 2000;96:91-8.
5. Denys D, van Megen H, Westenberg GM. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder. An open-label study. J Clin Psychiatry 2002;63:700-3.
6. Hollander E, Rossi NB, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: A double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2003;6:397-401.
7. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind placebo-controlled study of risperidone addiction in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000;57:794-801.
8. Stein DJ, Bouwer C, Hawkridge S, Emsley RA. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997;58:119-22.
9. Onrust SV, McClellan K. Perospirone. CNS Drugs 2001;15:329-38.
10. Ishibashi T, Ohno Y. Perospirone hydrochloride; The novel atypical antipsychotic agents with high affinities for 5-HT2, D2 and 5-HT1A receptors. Biogenic Amines 2004;18:307-17.
11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
12. Goodman WK, Price L, Rasmussen SA, Mazure C, Fleishmann RL, Hill C, et al. The Yale-Brown Obsessive-Compulsive Scale, I: Development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-11.
13. Goodman WK, Price L, Rasmussen SA, Mazure C, Delgado P, Heninger GR, et al. The Yale-Brown Obsessive-Compulsive Scale, II: Validity. Arch Gen Psychiatry 1989;46:1012-6.
14. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965;12:63-70.
15. Denys D, van der Wee N, Janssen J, De Geus F, Westenberg GM. Low level of Dopamine D2 receptor binding in obsessive-compulsive disorder. Biol Psychiatry 2004;55:1041-5.
16. Shiwa T, Amano T, Matsubayashi H, Seki T, Sasa M, Sakai N. Perospirone, a novel antipsychotic agent, hyperpolarizes rat dorsal raphe neurons via 5-HT1A receptor. J Pharmacol Sci 2003;93:114-7.
17. Sumiyoshi T, Matsui M, Tamashita I, et al. Effect of adjunctive treatment with serotonin 1A agonist tandospirone on memory functions in schizophrenia. J Clin Pharmacol 2000;20:386-8.
18. Jenike MA, Baer L, Buttolph L. Buspirone augmentation of fluoxetine in patients with obsessive-compulsive disorder. J Clin Psychiatry 1991;52:13-4.
19. Markowitz PJ, Stagno SL, Calabrese JR. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry 1990;147:798-800.
20. Pigott TA, L'Heureux F, Hill JL, Bihari K, Bernstein SE, Murphy DL. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992;12:11-8.
21. Thomsen PH, Mikkelsen HU. The addiction of buspirone to SSRI in the treatment of adolescent obsessive-compulsive disorder. Eur J Child Adolesc Psychiatry 1999;8:143-8.
22. McAskill R, Mir S, Taylor D. Pindolol augmentation of antidepressant therapy. Br J Psychiatry 1998;173:203-8.
23. Jeste DV, Dolder CR. Treatment of non-schizophrenic disorders: Focus on atypical antipsychotics. J Psychiatr Res 2004;38:73-103.
24. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of evidence. Neuropsychopharmacology 1998;18:63-101.
25. Canas F. Mechanisms of action of atypical antipsychotics. CNS Spectrum 2005;10(Suppl 10):5-11.
26. Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A. Obsessive-compulsive symptoms induced by atypical antipsychotics; A review of the reported cases. Prog Neuro-Psychopharmacol Biol Psychiatry 2003;27:333-46.